Author

Douglas K Graham

Children's Healthcare of Atlanta/Emory University - Cited by 6,863 - Cancer Biology

Biography

Douglas K. Graham, MD, Ph.D., is the chief and William G. Woods, MD Chair of the Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta. Dr. Graham also serves as chief of the Division of Pediatric Hematology/Oncology/BMT.
Title
Cited by
Year
MERTK in cancer therapy: targeting the receptor tyrosine kinase in tumor cells and the immune system
JM Huelse, DM Fridlyand, S Earp, D DeRyckere, DK GrahamPharmacology & therapeutics 213, 107577, 2020202
33
2020
BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway
AL Green, J DeSisto, P Flannery, R Lemma, A Knox, M Lemieux, ...Oncogene 39 (11), 2305-2327, 2020202
26
2020
Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies
JF Merola, KA Papp, P Nash, J Gratacós, WH Boehncke, D Thaçi, ...Journal of the European Academy of Dermatology and Venereology 34 (12), 2809 …, 2020202
14
2020
OP0107 Etanercept withdrawal and re-treatment in patients with inactive non-radiographic axial spondyloarthritis at 24 weeks: results of re-embark, an open-label, phase IV trial
F Van den Bosch, JCC Wei, P Nash, FJ Blanco, D Graham, C Zang, ...Annals of the Rheumatic Diseases 79 (Suppl 1), 70-70, 2020202
12
2020
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
D Yan, HS Earp, D DeRyckere, DK GrahamCancers 13 (22), 5639, 2021202
11
2021
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
D Yan, JM Huelse, D Kireev, Z Tan, L Chen, S Goyal, X Wang, SV Frye, ...The Journal of Clinical Investigation 132 (15), 2022202
8
2022
Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia
M Lee, JAG Hamilton, GR Talekar, AJ Ross, L Michael, M Rupji, ...Nature Communications 13 (1), 115, 2022202
7
2022
UNC5293, a potent, orally available and highly MERTK-selective inhibitor
UNC593, a potent, orally available and highly MERTK-selective inhibitorH Zheng, J Zhao, B Li, W Zhang, MA Stashko, KA Minson, MG Huey, ...European Journal of Medicinal Chemistry 0, 113534, 010
2
2021
AB0827 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS
AB087 IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITISCT Ritchlin, A Ogdie, JT Giles, JJ Gomez-Reino, P Helliwell, L Stockert, ...Annals of the Rheumatic Diseases 79 (Suppl 1), 1717-1718, 000
2
2020
Single cell transcriptomics revealed AML and non-AML cell clusters relevant to relapse and remission in pediatric AML
BE Thomas, P Perumalla, SS Bhasin, D Sarkar, B Dwivedi, SI Park, ...Blood 136, 4-5, 000
2
2020
Characterization of T-ALL-Specific Heterogenous Blast Populations Using High Resolution Single Cell Profiling
SS Bhasin, RJ Summers, BE Thomas, D Sarkar, B Dwivedi, SI Park, ...Blood 136, 11-1, 000
2
2020
Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment
J Cruz Cruz, KC Allison, LS Page, AJ Jenkins, X Wang, HS Earp, SV Frye, ...Frontiers in Immunology 14, 114671, 030
2
2023
Comprehensive genomic profiling of high-risk pediatric cancer patients has a measurable impact on clinical care
RJ Summers, SM Castellino, CC Porter, TJ MacDonald, GD Basu, ...JCO Precision Oncology 6, e100451, 0
2
2022
A novel strategy to cope with osimertinib resistance in non-small cell lung cancer by treatment with a PIM kinase inhibitor in combination with a MERTK-selective kinase inhibitor
D Yan, Z Tan, X Wang, SV Frye, HS Earp III, D DeRyckere, DK GrahamCancer Research 8 (3_Supplement), 09-09, 20220
1
2021
Analysis of Single Cell Transcriptomics in Paired Pediatric T-ALL Samples Collected at Diagnosis and Following End of Induction Therapy Reveals an MRD-Associated Stem Cell …
SS Bhasin, BE Thomas, RJ Summers, D Sarkar, HL Mumme, ME Mansour, ...Blood 38, 3, 20220
1
2021
Pediatric Single Cell Cancer Atlas: An Integrative Web-Based Resource for Single Cell Transcriptome Data from Pediatric Leukemias
HL Mumme, SS Bhasin, BE Thomas, B Dwivedi, D DeRyckere, ...Blood 38, 3488, 20220
1
2021
Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
RJ Summers, J Jain, E Vasileiadi, B Smith, M Stout, J Kelvin, X Wang, ...Blood 38, 84, 20220
1
2021
MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib
D Yan, J Huelse, R Parker, Z Tan, X Wang, SV Frye, HS Earp, ...Cancer Research 80 (6_Supplement), 882-882, 2020202
1
2020
512 Patient and disease characteristic predictors of systemic exposure to crisaborole
52 Patient and disease characteristic predictors of systemic exposure to crisaboroleV Purohit, JL Werth, D Graham, T NicholasJournal of Investigative Dermatology 40 (7), S70, 2020202
1
2020
MERTK inhibition induces an anti-leukemia dendritic cell-T cell axis while TYRO3 inhibition protects through a separate mechanism
JM Huelse, SS Bhasin, BE Thomas, ML Chimenti, X Wang, SV Frye, ...Cancer Research 82 (2_Supplement), 240-240, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=5nXApu0AAAAJ&hl=en

Cited by
Citations 6863
h-index 41
i10-index 80
Recommended Journals
Open Access Journals